Maze Therapeutics, Inc. cotiza a 26.87 USD y tiene una capitalización bursátil de $1.5B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial…
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.76 | $-0.65 |
| Estimado | $-0.75 | $-0.70 | $-0.70 | $-0.69 |
| Sorpresa | — | — | -8.6% | +5.8% |
| Métrica | MAZE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -36.9% | -40.4% | +3.5% |
| ROA | -33.0% | -32.0% | -1.0% |
| Current Ratio | 15.50 | 2.84 | +12.66 |
| Debt / Equity | — | 0.28 | — |